Sbraccia, Paolo https://orcid.org/0000-0001-9634-1501
Busetto, Luca
Santini, Ferruccio
Mancuso, Mariarosaria
Nicoziani, Paolo
Nicolucci, Antonio
Clinical trials referenced in this document:
Documents that mention this clinical trial
Changing the narrative around obesity in the UK: a survey of people with obesity and healthcare professionals from the ACTION-IO study
https://doi.org/10.1136/bmjopen-2020-045616
Misperceptions and barriers to obesity management: Italian data from the ACTION-IO study
https://doi.org/10.1007/s40519-020-00907-6
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 13 February 2020
Accepted: 15 April 2020
First Online: 8 May 2020
Compliance with ethical standards
:
: Dr. Sbraccia reports grants from Novo Nordisk during the conduct of the study. Dr. Busetto reports grants from Enzymmanagement AG, personal fees from Novo Nordisk, and personal fees from Bruno Farmaceutici S.p.A., outside the submitted work. Dr. Santini reports personal fees and participation in this trial from Novo Nordisk, and personal fees from BrunoPharma, personal fees from Aegerion, participation in clinical trials with Damor Pharmaceuticals, grants from BioItalia S.p.A., outside the submitted work. Dr. Mancuso and Dr. Nicoziani are Novo Nordisk employees. Dr. Nicolucci reports grants from Novo Nordisk, during the conduct of the study.
: In Italy, ethical approval was determined to be non-essential for a study of this nature based on regulatory standards and precedent. This study was performed in accordance with the ethical standards of the Declaration of Helsinki. All procedures in this study complied with the laws and regulations regarding the management of personal information as required by Italy and the European General Data Protection Regulation.
: Electronic informed consent was obtained from all the individual participants before they were included in this study.